FDA Approved: OXERVATE — Original Application (Domp farmaceutici S.p.A.)

View source ↗

Summary

FDA approved Oxervate (cenegermin-bkbj) from Dompé Farmaceutici as a first-in-class therapy for neurotrophic keratitis, a rare corneal disease.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Neurotrophic Keratitis

Drugs mentioned

• Oxervate (cenegermin)

Snippet

ORIG AP for OXERVATE (CENEGERMIN-BKBJ)